Skip to main content

Advertisement

Log in

Idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN): case series of three patients with multimodal imaging

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to report the clinical presentation, disease progression, treatment and complications of IRVAN.

Method

Case series

Patients

Six eyes from three patients were included.

Results

All eyes were treated with pan-retinal photocoagulation (PRP). One eye received Ozurdex (dexamethasome implant) for persistent macular exudates and oedema. One eye received Avastin injections for retinal neovascularization. Oral steroids were given to all patients at some point during the disease process. One patient had additional immunosuppression with mycophenolate mofetil. Despite aggressive PRP, the visual outcomes varied widely. One patient maintained 6/6 vision bilaterally at 84 months follow-up. The second patient had progressive visual loss secondary to macular exudates and oedema, from 6/9 right eye, 6/6 left eye to 6/18 right eye, 6/60 left eye within 12 months despite Ozurdex injection. The third patient’s vision at presentation was 6/5 right eye, and 6/4 left eye. Despite further interventions including Avastin and mycophenolate mofetil, he continued to have progressive neovascularization and recurrent vitreous haemorrhage. At 72 months, his vision had deteriorated to 6/60 right eye, 6/18 left eye.

Conclusion

The progression of IRVAN can vary greatly, in spite of aggressive treatment with PRP, oral and intravitreal steroids, immunosuppressant medication and anti-VEGF agents. The variation in disease progression occurs both within the same individual as well as between individuals. An individualised approach to therapy is advocated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Chang TS, Aylward GW, Davis JL et al (1995) Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Ophthalmology 102(7):1089–1097

    Article  CAS  PubMed  Google Scholar 

  2. Samuel MA, Equi RA, Chang TS et al (2007) Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): new observations and a proposed staging system. Ophthalmology 114(8):1526–9.e1

    Article  PubMed  Google Scholar 

  3. Sigler EJ, Grosso A (2016) Idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome. Retina Phila Pa 36(3):e16–e17

    Article  Google Scholar 

  4. Banaee T, Hosseini SM (2015) Optical coherence tomography features in idiopathic retinal vasculitis, aneurysms and neuroretinitis syndrome. J Ophthalmic Vis Res 10(2):193–196

    Article  PubMed  PubMed Central  Google Scholar 

  5. Marín-Lambíes C, Gallego-Pinazo R, Salom D et al (2012) Rapid regression of exudative maculopathy in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis syndrome after intravitreal ranibizumab. Case Rep Ophthalmol 3(2):251–257

    Article  PubMed  PubMed Central  Google Scholar 

  6. Saatci AO, Ayhan Z, Take_ Ö et al (2015) Single bilateral dexamethasone implant in addition to panretinal photocoagulation and oral azathioprine treatment in IRVAN syndrome. Case Rep Ophthalmol 6(1):56–62

    Article  PubMed  PubMed Central  Google Scholar 

  7. Basha M, Brown GC, Palombaro G et al (2014) Management of IRVAN syndrome with observation. Ophthalmic Surg Lasers Imaging Retina 45 Online:e18–e22

    PubMed  Google Scholar 

  8. Ferris F (1996) Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 94:505

  9. Akesbi J, Brousseaud FX, Adam R et al (2010) J.P. Intravitreal bevacizumab (Avastin®) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis. Acta Ophthalmol 88(2):e40–1

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu Jeat Chong.

Ethics declarations

Conflict of interest

Dr. Erika Marie Damato has received speaker fees from AbbVie and Novartis in the past 12 months. All the other authors declare that they have no conflict of interest

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Consent not required due to retrospective, anonymous and observational nature of this series. The study was performed at the Birmingham Midland Eye Centre. This research was presented at the European Association for Vision and Eye Research conference in NICE (2017). There are no proprietary interests to declare.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chong, Y.J., Logeswaran, A., Sarmad, A. et al. Idiopathic retinal vasculitis, aneurysms and neuroretinitis (IRVAN): case series of three patients with multimodal imaging. Graefes Arch Clin Exp Ophthalmol 257, 1013–1018 (2019). https://doi.org/10.1007/s00417-019-04291-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-019-04291-5

Keywords

Navigation